Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead

ASSEMBLY BIOSCIENCES, INC.

Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).
Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.
Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.
Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.
Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.